Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Potential effects of age on screening for primary aldosteronism

Journal of Human Hypertension volume 30, pages 53–61 (2016)Cite this article

Subjects

Abstract

Aldosterone/renin ratio (ARR) is currently regarded as the most reliable and available screening test for primary aldosteronism (PA), however, the falling accuracy of ARR with increasing age has posed crucial challenge for PA screening among older-aged population. To clarify potential effects of age on screening for PA, 216 subjects with PA and 657 subjects with non-PA were recruited and subdivided into four age groups (⩽39, 40–49, 50–59 and ⩾60 years) and their biochemical parameters were compared. As expected, plasma renin activity (PRA) lowered more than plasma aldosterone concentration (PAC) and led to gradually elevated ARR with increasing age in the non-PA group (P<0.001), whereas this phenomenon was unconspicuous in the PA group. The best cut-off values of ARR for PA screening were elevated in subjects ⩾50 years, whereas the area under the receiver operating characteristic curves (AUCs), sensitivity, specificity and Youden's index (YI) of ARR were declined with increasing age, especially in patients ⩾60 years (AUC=0.863, sensitivity=95.2%, specificity=69.0%, YI=0.643). The AUCs of PAC increased with increasing age and even slightly surpassed that of ARR in patients ⩾60 years (AUCPAC=0.884). Our data suggest that the criteria of ARR for PA screening in patients ⩾50 years may need setting higher; the falling accuracy of ARR with increasing age, especially in patients ⩾60 years, could be improved by taking into account the absolute value of the PAC when applicable by the center.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C et al. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293–2300.

    Article  CAS  Google Scholar 

  2. Young WF . Primary aldosteronism. Clin Endocrinol 2007; 66: 607–618.

    Article  CAS  Google Scholar 

  3. Hannemann A, Wallaschofski K . Prevalence of primary aldosteronism in patient cohort and in population-based studies: a review of the current literature. Horm Metab Res 2012; 44: 157–162.

    Article  CAS  Google Scholar 

  4. Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371: 1921–1926.

    Article  CAS  Google Scholar 

  5. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the american heart association professional education committee of the council for high blood pressure research. Hypertension 2008; 51: 1403–1419.

    Article  CAS  Google Scholar 

  6. Florczak E, Prejbisz A, Szwench-Pietrasz E, Sliwiński P, Bieleń P, Klisiewicz A et al. Clinical characteristics of patients with resistant hypertension: the RESIST-POL study. J Hum Hypertens 2013; 27: 678–685.

    Article  CAS  Google Scholar 

  7. Muiesan ML, Salvetti M, Paini A, Bhatia V, Papacosta O, Walker M et al. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension 2008; 52: 529–534.

    Article  CAS  Google Scholar 

  8. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006; 48: 232–238.

    Article  CAS  Google Scholar 

  9. Fallo F, Pilon C, Urbanet R . Primary aldosteronism and metabolic syndrome. Horm Metab Res 2012; 44: 208–214.

    Article  CAS  Google Scholar 

  10. Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens 2003; 21: 2149–2157.

    Article  CAS  Google Scholar 

  11. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L et al. Increased diagnosis of primaryaldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89: 1045–1050.

    Article  CAS  Google Scholar 

  12. Stowasser M, Taylor PJ, Pimenta E, Ahmed AH, Gordon RD . Laboratory investigation of primary aldosteronism. Clin Biochem Rev 2010; 31: 39–56.

    PubMed  PubMed Central  Google Scholar 

  13. Stowasser M, Ahmed AH, Pimenta E, Taylor PJ, Gordon RD . Factors affecting the aldosterone/renin ratio. Horm Metab Res 2012; 44: 170–176.

    Article  CAS  Google Scholar 

  14. Fommei E, Ghione S, Ripoli A, Maff ei S, Di Cecco P, Iervasi A et al. The ovarian cycle as a factor of variability in the laboratory screening for primary aldosteronism in women. J Hum Hypertens 2009; 23: 130–135.

    Article  CAS  Google Scholar 

  15. Pizzolo F, Raffaelli R, Memmo A, Chiecchi L, Pavan C, Guarini P et al. Effects of female sex hormones and contraceptive pill on the diagnostic work-up for primary aldosteronism. J Hypertens 2010; 28: 135–142.

    Article  CAS  Google Scholar 

  16. Ahmed AH, Gordon RD, Taylor PJ, Ward G, Pimenta E, Stowasser M . Are women more at risk of false-positive primary aldosteronism screening and unnecessary suppression testing than men? J Clin Endocrinol Metab 2011; 96: E340–E346.

    Article  CAS  Google Scholar 

  17. Crane MG, Harris JJ . Effect of aging on renin activity and aldosterone excretion. J Lab Clin Med 1976; 87: 947–959.

    CAS  PubMed  Google Scholar 

  18. Tsunoda K, Abe K, Goto T, Yasujima M, Sato M, Omata K et al. Effect of age on the renin-angiotensin-aldosterone system in normal subjects: simultaneous measurement of active and inactive renin, renin substrate, and aldosterone in plasma. J Clin Endocrinol Metab 1986; 62: 384–389.

    Article  CAS  Google Scholar 

  19. Olivieri O, Ciacciarelli A, Signorelli D, Pizzolo F, Guarini P, Pavan C et al. Aldosterone to renin ratio in a primary care setting: the bussolengo study. J Clin Endocrinol Metab 2004; 89: 4221–4226.

    Article  CAS  Google Scholar 

  20. Yin G, Zhang S, Yan L, Wu M, Xu M, Li F et al. Effect of age on aldosterone/renin ratio (ARR) and comparison of screening accuracy of ARR plus elevated serum aldosterone concentration for primary aldosteronism screening in different age groups. Endocrine 2012; 42: 182–189.

    Article  CAS  Google Scholar 

  21. Nakama C, Kamide K, Kawai T, Hongyo K, Ito N, Onishi M et al. The influence of aging on the diagnosis of primary aldosteronism. Hypertens Res 2014; 37: 1062–1067.

    Article  CAS  Google Scholar 

  22. Funder JW, Carey RM, Fardella C, Gomez-Sanchez C, Mantero F, Stowasser M et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 3266–3281.

    Article  CAS  Google Scholar 

  23. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J . Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217–223.

    Article  Google Scholar 

  24. Young WF . Management approaches to adrenal incidentalomas: a view from Rochester, Minnesota. Endocrinol Metab Clin North Am 2000; 29: 159–185.

    Article  Google Scholar 

  25. Gijón-Conde T, Graciani A, Banegas JR . Resistant hypertension: demography and clinical characteristics in 6292 patients in a primary health care setting. Rev Esp Cardiol 2014; 67: 270–276.

    Article  Google Scholar 

  26. Taylor PJ, Cooper DP, Gordon RD, Stowasser M . Measurement of aldosterone in human plasma by semiautomated HPLC-tandem mass spectrometry. Clin Chem 2009; 55: 1155–1162.

    Article  CAS  Google Scholar 

  27. Stowasser M, Gordon RD . Primary aldosteronism-careful investigation is essential and rewarding. Mol Cell Endocrinol 2004; 217: 33–39.

    Article  CAS  Google Scholar 

  28. Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N et al. Guidelines for the diagnosis and treatment of primary aldosteronism—The Japan Endocrine Society 2009. Endocr J 2011; 58: 711–721.

    Article  CAS  Google Scholar 

  29. Rossi GP, Dalla CàA . Clinical management of primary aldosteronism. 2013 practical recommendations of the Italian Society of Hypertension (SIIA). High Blood Press Cardiovasc Prev 2014; 21: 71–75.

    Article  CAS  Google Scholar 

  30. Westerdahl C, Bergenfelz A, Isaksson A, Valdemarsson S . Captopril suppression: limitations for confirmation of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2011; 12: 326–332.

    Article  CAS  Google Scholar 

  31. Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C et al. Comparison of the Captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension 2007; 50: 424–431.

    Article  CAS  Google Scholar 

  32. Ahmed AH, Cowley D, Wolley M, Gordon RD, Xu S, Taylor PJ, Stowasser M . Seated saline suppression testing for the diagnosis of primary aldosteronism: a preliminary study. J Clin Endocrinol Metab 2014; 99: 2745–2753.

    Article  CAS  Google Scholar 

  33. Kuo CC, Balakrishnan P, Hsein YC, Wu VC, Chueh SC, Chen YM et al. The value of losartan suppression test in the confirmatory diagnosis of primary aldosteronism in patients over 50 years old. J Renin Angiotensin Aldosterone Syst 2014 (e-pub ahead of print 16 July 2014; pii: 1470320313498632).

  34. Ahmed AH, Gordon RD, Ward G, Wolley M, Kogovsek C, Stowasser M . Should aldosterone suppression tests be conducted during a particular phase of the menstrual cycle, and, if so, which phase? Results of a preliminary study. Clin Endocrinol 2014 (e-pub ahead of print 19 December 2014; doi:10.1111/cen.12705.

  35. Fischer M, Baessler A, Schunkert H . Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res 2002; 53: 672–677.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by Grant 81450011 from the National Natural Science Foundation of China.

No interventions were used in this study.

Author information

Authors and Affiliations

  1. Hypertension Institute of Xinjiang, Hypertension Center of the People's Hospital Of Xinjiang Uygur Autonomous Region, Urumqi, China

    Q Luo, N-f Li, X-g Yao, D-l Zhang, S-f-y Abulikemu, G-j Chang, K-m Zhou, G-l Wang, M-h Wang, W-j Ouyang, Q-y Cheng & Y Jia

Authors
  1. Q Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N-f Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. X-g Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D-l Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S-f-y Abulikemu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G-j Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K-m Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G-l Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M-h Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. W-j Ouyang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Q-y Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Y Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N-f Li.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Luo, Q., Li, Nf., Yao, Xg. et al. Potential effects of age on screening for primary aldosteronism. J Hum Hypertens 30, 53–61 (2016). https://doi.org/10.1038/jhh.2015.21

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2015.21

This article is cited by

Search

Advanced search

Quick links